Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)
- On the first day, study participants will undergo 2 MRI examinations. A scan will be
done prior to administration of the contrast agent (Feraheme) and then a second scan
immediately after administration. On the second day, study participants will be asked
to return for a third MRI.
- All MRI scans will be done at Massachusetts General Hospital.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To determine the sensitivity and specificity of high resolution magnetic resonance imaging with lymphotrophic superparamagnetic nanoparticles to identify small and otherwise undetectable lymph node metastases.
Ralph Weissleder, MD, PhD
Massachussetts General Hospital
United States: Institutional Review Board
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|